Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | AML: multiple problems requiring combined therapy

Francesco Lo-Coco • 22 Jun 2017
EHA 2017
Acute Myeloid Leukemia

Francesco Lo-Coco, MD from University Tor Vergata Rome, Rome, Italy explains how acute myeloid leukemia (AML) consists of multiple genetic lesions when compared to other haematological malignancies like acute promyelocytic leukemia (APL). This has resulted in conventional therapies having to be combined in order to disrupt tumour cells, rather than treatment directed at a single target. This interview was recorded at the European Hematological Association (EHA) 2017 in Madrid, Spain.

More from Francesco Lo-Coco

3:58
Targeted treatments for AML: the revolution
Francesco Lo-Coco • 10 Dec 2017
3:41
Advancements in APL treatment: oral ATO, MRD and treatment objectives
Francesco Lo-Coco • 10 Dec 2017
2:06
APL: getting the perfect picture
Francesco Lo-Coco • 10 Dec 2017
1:57
The standardization of molecular diagnostics for myeloid diseases in Italy
Francesco Lo-Coco • 5 Oct 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals